Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Other cancers Clinical Trials

Protocol Number Title
2003NT036
ALTE03N1 Key Adverse Events After Childhood Cancer (COG study)
2003NT049
ABTR01B1 A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors
2006LS032
MT2005-21 Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
2008NTCG101
COG ANBL00B1 "Neuroblastoma Biology Studies"
2009NTCG026
COG ALTE05N1 Umbrella Long-Term Follow-Up Protocol
2009NTUC092
MT2010-09 Primary Immune Deficiency Treatment Consortium (PIDTC). PROJECT 1: A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children with SCID Disorders (RDCRN PIDTC #6901)
2009NTUC093
MT2011-02R A Retrospective and Cross-Sectional Study of Hematopoietic Cell Transplantation for SCID (PIDTC 6902)
2010NTLS145
MT2007-05R Late Effects in Survivors of Cancer, Stem Cell Transplantation or Blood Disorders
2011NTLS041
Molecular Epidemiology of Pediatric Germ Cell Tumors
2011OC057
MT2011-09C Alkylator-Intense Conditioning Followed By Autologous Transplantation for Patients with High Risk or Relapsed Solid or CNS Tumors
2011OC140
MT2011-21C Laronidase (Aldurazyme TM) Enzyme Replacement Therapy (ERT) with Hematopoietic Stem Cell Transplantation (HSCT) for Hurler Syndrome (MPS IH)- PI Orchard
2012CG091
COG ADVL1212 - A Phase I Study of Crizotinib in Combination with Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma. ADVL1212 Study Chair: NIH COG Phase I Grant (UMCA097452) ADVL1212 - Pfizer No. WS2274618
2013CG032
COG ANBL1221: A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC # 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 764038, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma
2013NTUC125
MT2013-36R: PIDTC 6904: Analysis of Patients Treated for Wiskott-Aldrich Syndrome Since January 1, 1990 (PIDTC 6904)
2014CG036
COG ADVL1411 - A Phase 1/ 2 Study of BMN 673 (IND# 121510), an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children with Refractory or Recurrent Malignancies
2014CG067
ANBL1232 - Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High- Risk Neuroblastoma
2014IS062
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutation (MEK116540)
2014LS020
MT2014-12:Phase I/II Study of Human Chorionic Gonadotropin and Epidermal Growth Factor Supplementation (Pregnyl?) to Support Tolerance and Repair As Adjunct Therapy in High-Risk or Refractory Acute Graft-Versus-Host Disease
2014NTIS101
MT2014-32R: ALD-103 : A Prospective and Partially Retrospective Study to Evaluate Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Childhood Cerebral Adrenoleukodystrophy
2014NTLS071
Family-based studies of susceptibility to early onset disease
2014OC034
MT2014-10C : Allogeneic Hematopoietic Stem Cell Transplant for Patients with High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders
2015CG175
COG ADVL1416 - A PHASE 1 STUDY OF RAMUCIRUMAB, A HUMAN MONOCLONAL ANTIBODY AGAINST THE VASCULAR ENDOTHELIAL GROWTH FACTOR-2 (VEGFR-2) RECEPTOR IN CHILDREN WITH REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS "ADVL1416 ? Eli Lilly and Company"
2015NTCG168
COG APEC14B1 The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
2016IS002
A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors (I5B-MC-JGDN)

24 trials displayed